Skip to content
Home
About Us
Management Team
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Publications
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
Home
About Us
Management Team
Scientific Advisory Board
Board of Directors
Technology
Pipeline
Osteoporosis
Hypoparathyroidism
SBS & Obesity
Publications
Investors
Share Information
Share Chart
Email Alerts
Press Releases
SEC Filing
Investor Calendar
Corporate Governance
Board of Directors
Management
Committee Composition
Investor Resources
Investor FAQs
Document Request
Email Alerts
Corporate Presentation
Contact Us
Publications
Osteoporosis
2024 ASBMR Poster
2024 JBMR Editorial
2024 Entera Phase 2 Osteoporosis Paper in JBMR
2023 ASBMR Poster 1
2023 ASBMR Poster 2
2022 ASBMR Poster
Hypoparathyroidism
2024 ENDO Poster
2021 June, Entera Hypo Paper in JBMR
2019 ASBMR Poster
Platform
Technology
The Combined Effect of Permeation Enhancement and Proteolysis Inhibition on the Systemic Exposure of Orally Administrated Peptides
Other Targets
Oral Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like-Peptide-2 Analog (Teduglutide) - A Novel Approach for Injection-Free Treatment of Short Bowel Syndrome
